Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?

Adriano Venditti*, Robert Peter Gale, Francesco Buccisano, Gert Ossenkoppele

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)963-965
Number of pages3
JournalLeukemia
Volume34
Issue number4
DOIs
Publication statusPublished - 1 Apr 2020

Cite this